pharmaphorum
JULY 5, 2022
AstraZeneca has signed a deal to buy US biotech TeneoTwo in a deal worth up to $1.27 billion that will boost its position therapies for haematological cancers. The big pharma is paying $100 million upfront for the company, and offering up to $805 million in milestone payments if TeneoTwo’s drug candidates meet development objectives, plus up to $360 million if they hit sales targets.
European Pharmaceutical Review
JULY 5, 2022
After more than 20 years of environmental action, Pfizer has committed to further reduce its greenhouse gas (GHG) emissions and aims to achieve the voluntary Net-Zero Standard by 2040 – a full 10 years ahead of the standard’s proposed timeline. To achieve these goals, Pfizer aims to decrease its GHG emissions by 95 percent and its value chain emissions by 90 percent from 2019 levels by 2040.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
JULY 5, 2022
Trial organisers face intense competition to find and recruit eligible patients for atopic dermatitis studies. With more than 500 dermatology clinical trials currently underway, it is often heard that there is a ‘’competition for participants’’. Yet evidence from research studies and a survey with 4,000+ atopic dermatitis patients conducted by Clariness shows that this ‘race to recruit’ is actually not the primary reason for the growing discontinuation rate of atopic dermatitis trials.
European Pharmaceutical Review
JULY 5, 2022
Hereditary angioedema (HAE) is a genetic disorder, estimated to affect 1 in 50,000 people. It can lead to painful attacks of oedema (swelling) in various parts of the body, including the abdomen, face, feet, genitals, hands and throat. The main objective of the Phase III SPRING study ( NCT04070326 ) was to evaluate the safety and pharmacokinetics of Takhzyro ® (lanadelumab) – a fully human monoclonal antibody that specifically binds and decreases plasma kallikrein – in HAE patients aged two t
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
pharmaphorum
JULY 5, 2022
Cell therapy specialist Mogrify has struck a deal with Japanese drugmaker Astellas to look at ways to deploy regenerative medicine to treat hearing loss caused by factors such as chronic exposure to loud noises. The two partners will take an in vivo approach to the problem of so-called sensorineural hearing loss (SNHL) looking at ways to replace sound-detecting hair cells in the inner ear (cochlea) that become damaged in this type of deafness.
PharmaVoice
JULY 5, 2022
In a unanimous decision, a CDC committee calls for a preferential flu vaccine recommendation for people aged 65 and older for the first time.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
European Pharmaceutical Review
JULY 5, 2022
Bacterial spores are a significant concern for aseptic pharmaceutical manufacturers due to their ubiquitous nature and intrinsic resistance to environmental stressors such as heat, as well as chemical and radiation inactivating strategies. As much as 10 percent of microbes in a pharmaceutical cleanroom are spore-forming bacteria, with strains such as Bacillus species, able to cause human disease.
Pharmacy Times
JULY 5, 2022
Andre Harvin, PharmD, MS, executive director of Pharmacy, Oncology Services at Cone Health, discusses methods of accomplishing greater workforce diversity in the field of oncology pharmacy.
European Pharmaceutical Review
JULY 5, 2022
The Impact ® brand includes 30 Sanofi medicines and covers a wide range of therapeutic areas, including diabetes, cardiovascular disease, tuberculosis, malaria and cancer. Medicines include insulin, glibenclamide and oxaliplatin, the company said. Sanofi has also established an Impact fund to support startup companies and other innovators that can deliver scalable solutions for sustainable healthcare in underserved regions. .
PharmaVoice
JULY 5, 2022
AstraZeneca and Amgen are emphasizing diversity and authenticity in campaigns for lupus and severe asthma therapies.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
European Pharmaceutical Review
JULY 5, 2022
Stomach cancer, also known as gastric cancer, is the fifth most common type of cancer worldwide – and the third most common cause of death from cancer. 1 Approximately half of all cases occur in eastern Asia, but thanks to more advanced screening programmes in countries like Japan, survival rates in these regions are improving compared with western countries.
Pharmaceutical Commerce
JULY 5, 2022
Dr. Frank Doyle, Dean of the Paulson School of Engineering and Applied Sciences at Harvard University, outlines his recommendations for Fortune 500 c-suites as they strive to attract, develop, and retain the best talent for their upcoming 2023 strategic plans.
Pharmacy Times
JULY 5, 2022
Zahra Mahmoudjafari, PharmD, BCOP, DPLA; Alison Gulbis, PharmD, BCOP; and Kamakshi Rao, PharmD, BCOP, FASHP, discuss the underlying causes of the hematology-oncology pharmacist great migration from the field.
Pharmaceutical Technology
JULY 5, 2022
Sanofi has unveiled the global health brand, Impact, to make available standard of care treatments for non-profit supply to at-risk populations in low-income countries. Through the Impact brand, which comprises insulin, glibenclamide and oxaliplatin among others, the company will supply its 30 medicines in 40 lower-income countries in the world. The therapies cover a broad range of treatment areas, including diabetes, cardiovascular disease, tuberculosis, malaria and cancer and are regarded esse
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Pharmacy Times
JULY 5, 2022
This panel of experts navigates the effects of BTK inhibitors, and their impact on trpatients with Mantle Cell Lymphoma.
Pharmaceutical Technology
JULY 5, 2022
AstraZeneca has signed an agreement for the acquisition of all outstanding equity of TeneoTwo as well as its CD19/CD3 T-cell engager, TNB-486, in a deal worth up to $1.27bn to bolster the haematological cancer pipeline. As per the deal, AstraZeneca will make an upfront payment of $100m on the closing of the transaction. Furthermore, equity holders of TeneoTwo are entitled to get up to $805m in research and development (R&D)-based milestone payments as well as up to $360m as commercial-relate
Pharmacy Times
JULY 5, 2022
Pharmacy Times spoke with Paul Feuerstadt, MD, FACG, AGAF, about the investigative C. difficile treatment RBX2660.
NF2 BioSolutions
JULY 5, 2022
There are various different ways you can fundraise for us. Peoples Fundraising platform. Create a Facebook fundraiser for your birthday or add a fundraiser to your post (select NF2 BIOSOLUTIONS UK in both instances). Create a fundraiser on another platform (eg justgiving) and transfer the money raised into our account. Sign up to EasyFundraising or AmazonSmile, both these will donate a %age to us at NO extra cost to yourself.
Pharmacy Times
JULY 5, 2022
Drs Haumschild, Jain, and Wang discuss clinical pearls regarding BTK inhibitors, including drug interactions.
The deprescribing.org Blog
JULY 5, 2022
Hello, deprescribers! It has been some time since our last interview. Today we have a new one where we discuss a project called “Talking About Medications”. This is a workshop delivered by pharmacists that seeks to empower patients and their caregivers to participate in medications conversations with their healthcare providers. You can find more information about the workshops here.
pharmaphorum
JULY 5, 2022
UK health secretary Sajid Javid is giving up his position after a year in the role, saying in his resignation letter that he can “no longer, in good conscience, continue serving in this government.” His departure on its own would be a blow to Boris Johnson’s beleaguered premiership, but with Chancellor of the Exchequer Rishi Sunak also hitting the eject button, the prime minister looks more vulnerable than ever.
Pharmaceutical Technology
JULY 5, 2022
Researchers at the UNC School of Medicine have discovered that hepatitis A virus (HAV) replication needs particular interactions between the human protein ZCCHC14 and TENT4 poly(A) polymerases, a group of enzymes. The team also found that the oral compound, RG7834, developed by Hoffmann-La Roche, hindered replication at a crucial step, preventing the virus from infecting liver cells.
pharmaphorum
JULY 5, 2022
On the latest instalment of the pharmaphorum podcast, editor in chief Jonah Comstock hosts Tony Mack, CEO at Virpax Pharmaceuticals, in the virtual studio. . There were many causes for the opioid epidemic, but overreliance on a problematic drug category for pain management was one major factor. Mack – a veteran of several big pharmas and a three-time pharma entrepreneur – lays out the surprisingly complex business of pain management and discusses how a wider variety of drug modalities, as well
Pharmaceutical Technology
JULY 5, 2022
Mentions of the future of work within the filings of companies in the pharmaceutical industry were 373% higher between April 2021 and March 2022 than in 2016, according to the latest analysis of data from GlobalData. When pharmaceutical companies publish annual and quarterly reports, ESG reports and other filings, GlobalData analyses the text and identifies individual sentences that relate to disruptive forces facing companies in the coming years.
Outsourcing Pharma
JULY 5, 2022
Electronic health record solutions provider Athenahealth has partnered with Withings Health Solutions to put the RPM tech into place for clinical and care use.
Pharma Times
JULY 5, 2022
Treatment abstract focuses on results from a multiple ascending dose study in healthy volunteers
Outsourcing Pharma
JULY 5, 2022
On July 20, a collection of noted industry experts will lead a lively discussion on the rapid evolution of DCTs, and what advances might be on the horizon.
Pharma Times
JULY 5, 2022
C-Reactive protein test gets go-ahead for professional use across Europe
Outsourcing Pharma
JULY 5, 2022
AstraZeneca is to acquire US-based blood cancer specialist, TeneoTwo, in a deal worth around US$1.27bn.
pharmaphorum
JULY 5, 2022
Sanofi has said it will make 30 of its most commonly prescribed medicines available at non-profit prices to 40 lower-income countries, as part of a global health initiative launched by the company last year. The medicines – which include insulin, oral diabetes agent glibenclamide and cancer chemotherapy oxaliplatin – will be sold under a new Impact brand and are all classed as essential medicines by the World Health Organisation (WHO).
pharmaphorum
JULY 5, 2022
Cancer drugs will be flown from a facility in Portsmouth to a hospital on the Isle of Wight by drone, in the first pilot study of the technology by NHS England. The trial – announced this morning and said to be the first of its type worldwide – will mean that the lifesaving treatment can be picked up and dropped off to patients on the same day, said NHS chief executive Amanda Pritchard.
Expert insights. Personalized for you.
124 
Let's personalize your content